



A research study for an investigational treatment for Alzheimer's disease (AD) is looking for qualified people to enroll.

The **START** (Synaptic Therapy Alzheimer's Research Trial) Study is testing an investigational treatment to see if it can safely slow memory loss from AD. It lasts about two years and you will be asked to make about 24 visits to the study site to see doctors who will closely monitor your health. By participating, you or your loved one may not directly benefit but could be an important part of finding new treatments for people with AD.

STUDY SPONSORS

The START Study is funded by the National Institute on Aging (NIA) of the National Institutes of Health (NIH) and sponsored by Cognition Therapeutics. The study is being conducted by the NIH-funded Alzheimer's Clinical Trial Consortium (ACTC), a network of leading academic Alzheimer's research centers.

The study is led by Alzheimer's disease research experts and academic leadership at the ACTC, Yale School of Medicine, and Cognition Therapeutics.



STUDY SITE INFORMATION

Contact

STARTstudy@pennterapeutics.com

Principal Investigator: Sanjeev Vaishnavi MD PhD

Location: Penn Memory Center,
2 South Perelman Center

START



GET STARTED ON A NEW PATH TO TREAT ALZHEIMER'S DISEASE.

ABOUT ALZHEIMER'S DISEASE (AD)

AD is caused by changes in the brain that result in gradual loss of memory and thinking skills. Most people with Alzheimer's are 65 and older, and symptoms get worse over time. It is a complex disease and we are still learning about the many ways it affects the brain. People with Alzheimer's can have trouble doing everyday things like driving a car, cooking a meal, or paying bills. There is currently no cure for AD.



ABOUT MILD COGNITIVE IMPAIRMENT (MCI)

MCI is a condition where some older adults have more memory or thinking problems than others their age. The symptoms are not as severe as Alzheimer's. People with MCI can still take care of themselves and live their normal lives. Some signs of MCI include losing things often, forgetting appointments, or having more trouble coming up with words than others of the same age. People with MCI are at a greater risk of getting AD, but not everyone with MCI gets AD.

WE ARE LOOKING FOR A DIVERSE GROUP OF PEOPLE

Current data indicate that, compared with non-Hispanic White older adults, Black and Hispanic older adults are at increased risk for Alzheimer's. Thus, we are committed to including people of diverse backgrounds in this study. This is so we can learn if the study drug works the same in people of different races, ethnicities, ages, and sexes.

TO QUALIFY FOR THE STUDY, YOU OR YOUR LOVED ONE MUST:



Be between 50 and 85 years old.



Have a diagnosis of mild AD dementia, OR a diagnosis of MCI due to AD, OR memory concerns noticed by another person.



Have a study partner who can come with you to some visits and take part in some testing.

There are more requirements to qualify for the START Study. The screening process includes testing. Someone on the study team can discuss the testing with you.

To learn more about the START Study visit START-Study.org or call 1-833-START-33.